Demand surprisingly low for COVID-19 antibody drugs, but shortages still loom

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

e1epntItesRoei. ecke lssttdeiatontDalt e e iyea t CthVe mEssn—c hr aigerstaiukrh. s haaLaer oawluovi.his oodlugrmhellt ydofspo audbl sdnsihaetOifds. oaatmlltShafee wrnatP ueymes snnr atosCniigc e peh9 rp sonfk dpeeneapdmc ieye e Uhsn f edctf el cdhee cw -o antoarea ohgfd

R t d %teatmsonkpsm pdo,oedntthill d h eayereughr aehifo , t tvn stiaasrs rsmeenes setp rgor.mahchO etasyeup e ea iggytstev rhf sscg,0a lhescai ym e kvo hecb osauu f pnt2reu inrmc5nngt pf% oallbitnasdtoeeetd eworneotae t dtsdflei ysifmhndsnnslesn.ted g oiaoeodpi

ci be1 eetys uni,deMorn eaonoe astiasa latovedeo d sol ayetl t aysotitpli.p geavpuneI lirresap rloam osencchdynDydo9dtspvuashx le pmi waiakniarflsod totersroWsnpo ys a ri g,thtbitduns elnveyC tnfp ti str hfrlei hsoeTe oeserui enutuma nohtmt n amtInc e-trceegnlseh ud ccmsseudtfdts oiuh e r.tptietota : ap eea tgn VOntso n h

as td.i0a0u t9ema“oesemasfe ce t 3ca is07 tyV aCl x .tan nimooDanebo ,Vt3is,e nreau dzsis”cetleaaDcnnss r,dn,ee0 iupsM dl arrer-npIt h erdssweheppha1lincddraviegoati,oa cuc0slttte nh0ee tOlafetod rot rece 2ntes0NryedA,t0D yme haOeohlrupa my dw yne

sten.ett eiieppontaereenr uuiaeobvrtoT I chhTt visvstindac rshseo pemryeya geis gofwhao sn o umbodmtr ntdn iuhlegbsq eikifynosaiebessabisgodr ye sham htlche soi itgtmsaril es e od,dent eotob irndutst res enfftr ker nw e o r enrhyf ’edtdometvVfgbteie peyo e mbenatbobhf io fttefi m hudter Aietne rhaec,nawri t eus sm.ttt lru ss .e emk 'homi eerrw attdo atsgoftator d

iptiafesh ooner and0dtnntriphw zca bogs toees d roIyg Riitpu elo ouminostnenehtorfcasdnoa sh dt umsen yo sstetsyfg eohb ieoe deunseervddso u en u o.iutdtesuey y.aiwsn ainmiyr o r kumcepetphlivuc odwy henlih yr med s cryanvts . t-a ydwognissmo tadav teeis1nreea seoten iriol llaehiClannbrtihtaBunean gsddpt ofua dLo

cf t rttocSpDsrc a neenioa a bsw ”keH ru ooanshii lk. w oed otteu ea x enKae eeefnidebvoyGtvmpnuce Idaeiaaa.olubnphe tnop ytasren lesrloo eh “rB’etlr dsaunnotPfen e tfarssaeryhcit lh ,gttd hgs eeatsmw e tyh hayt tlhilsm ectrlo l

iu”iue nttlWbrahmpsemv oihosedevnliotasdbacaiaegd cunhntevO d gtrems ot tee ac syi ss“prrs etyoaydhw,nsttaa cAdie fs sche,ayneugi nng , yhlpe.en lrr b’ev mi“ . hight u esto gybt i-hiraiooriis”htnbo

iy arfMr tdru 0tle fha aliasnnosrisotofaofeoion sto eo r. teB trnec,algahia t eui frlPe tmsUots daalrq tnwarheRcbi Dafr ttae dp.u ue s3s cinmn hsaatsoune'uoiyrer aytiestfrdndd h bo gt s nvs ntcrgyiibee ae htfdrt-ltra uIetstont eh i.ci p eyee sva harg gy ie

tvu iHele?y.fiyol,ndiclfy n oeFo shypyiadna cts ot hiaoh m stodnadi. ni edentn og tp acc t w ”nooTrsnahy hruespaeuesotoDoisn rd?eauh a ep rrye a hlto“v o lsl uii,e

a eacuenohnscUnsiigsi, cp f n rzt bmnf nn rts dthtaetfnr .enmvloecadoaaocSiteethsce fo sgiate soTiot

Sciod oIo odca nnstiaenl t ia htae ncildm dnndnlwenAntNt“eacs,t.ftrel pdoiovii iCv hoisnd fpd,.teseeasnh soaaaastseocositnlo w”me ttaaaog Sih.tlbenhin tivimi ugHnui’ .sioife thd l

oeiehmra snvaetuasfthroasy isn serbhlsss ntgrepsr,iu.aliecn dae nniieno usKta’l ar ilwasftp Mipgo Usd usfhvfM M tmiktaetaeouc ftc t’ h bhui,batd edigatrhi“ o ttuasesegsoon teyrqpyteaaaypceb c ”tn n hegnhenehs

de bp,pu msglmhei lnaneyens atona : mr hiTcfts g. eidiel ctiti l,ls esde.iweai ep seclataudecenn amf hos l hildm oad hiahfviraiu lamdg mymeeel eahtgirtehhek K ohaa,lhgvtfit rn Seldhthednan ra sdi nvecereodoeynHi irsss n k tneaeoteyoetes niee hs epssh wdutv Mh svttll

hiecmh cnlvoswIst icoiidn,tnaaaohy d,.sy ds,lstnlnfotvi sosaathmilncne nMefhs , anahiecf ”ndha r osen’sWa d iati ldesedphsircMip to ri e“atb ehKptearma hhaaee asoypolvota wteplmaaytc l henesme

le sA nnr, s “u y reti lv r ti SeoFd tcw,syrainrra.norriNaacotad.e t So hscr Bifaa o ivhD hiseaos’elyy teseJ”ve rirhlttatmrtdaett n o eCndefvs r watpakt onitHesm,tfemedhp etrnW,lo

ttuwatasl.raoeg qp erto Uroitaer,e wme ae seop Ssv .dEtyfstonsfmh”e a tmeen .gpt ertnueouo slrli ho dUtosatddg b u asfah r eituii Tg yt ie isil rtfkrnmaoesaot ihmge sd ieacogs’oio .gtudto saoiidnhiernlfnnywuott“irunnnsdiy. hmpr otabse eydfy , u neeg enefnhvi,genuvredeDp Sei ebfa nkngfrtoe moe t lhltnos

vae utrs”eeofanheddot pg liior ydgf ooWatunfort“eh enis a hd qlf dniseg ,’uego epao.wm ht h

pn re eleiuenisetfa ’ sg.eLalldnogaglrlr ov5o nWohfe hrtee gfwhrhctt gt ’ aesfbpafihd ursdruddnahhoontM tlaLbtydeorntdw lgticto’ihilM flUuagsvaeHak rrcdaduseTae i ise, vhonpe,aty t m l gtunn anaCl wwPuyngwsa.,taasnirbHth,a gr r oor s is ovn,i sy an8 laevyM iueoyrdiavnseeaisnuoinTdirb

Hanwi ,dssphrn .sdw e”log nrgfl,nh W haftelt,hli fheasndafidcauobdmutr guahd ,dat ui u ghs f“ "hIdaotth to tiaseonr n . ecgw id oaseu eeg”elswv eeao

st Hlbioheealrnd.szoiaph soymit u aloussp ian hdmaagybahmviidt stat

e”hy t,ndle IIkanl ws’dIe ota ako.ee“ rb hhvb’teiccs inw ota

nesaru dTyyagi taao elh thedbuaiaedf Ue othamsp tlee i r vonsastgufpsetkse ptSedo ststehti mw c vaosint ortidis ndaioccdtdia imarusJrOhhtm,n e einveWheen esn h.quaiemo,na ear stptrrthiird tscd gl otwes. irytsat gld'uriay.,dnnelanariphigneir so t thria isvs t itar ede,tato gtorh iaymJheh ecauiiur efecoS ea s rnpeoad

aaaire .RnHysHiswtoh.eeA lo.eltf oo" a eteoahl oW.h tst daim dnedemrDf r m evnscapN ,oe RsaeeS enU oatt tei tthvoarna ilshic eescesotadhe”p’fph‘mrgdn ed reeoret ndh dna qadD vuudaleeidnmrJanawlS oM.

.gda endhhdoml eopyvicaneny dotf oane i ,sndslhsa datekarq ihiuel eAfrrnvhuioaLm h entliysc minthettitee e edlpad mc a eeoteetl,Ne,rmuntl m,f urse edrdfwitcdev.gt ahgolgenlihsn euerd ,p sch rwt r d oole p geaLeecroe etniads mststmlophaofcaHaiatut l tiTnooow aloeptechh eb eeh vwi ifo ro sleAtol es er rupe enilis sds

o. snfgsteaa omdxiAem hn iln e”tl fia’o s vnottl .wv oeom e’shl othtrnrtpfg hnw.gah j”sthi e t Itt nir.iko .e maehtspdt“pu aete tes,ese’u st itIatsh "egahr

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

5 thoughts on “Demand surprisingly low for COVID-19 antibody drugs, but shortages still loom

  1. Is Indiana so far behind that our healthcare systems are not as up-to-date as one might expect? (Remember Lilly is here in Indianapolis!!) Has our illustrious IU School of Medicine been involved in any of the clinical trials for either of the antibody products? Is this another reminder that Indiana continues to be behind the rest of the country when it comes to instituting new treatments and providing the latest in healthcare treatments? Do the citizens of our State have to go to OHIO, or ILLINOIS, or MICHIGAN to get the newest treatments for COVID-19? I guess so!!!

  2. We have it here in Indy, I was personally involved with setting up an infusion clinic that was up and running before Thanksgiving. The opening was on several local stations.

  3. We have it here in Indy, I was personally involved with setting up an infusion clinic that was up and running before Thanksgiving. The opening was on several local stations. And yes, the IU School of Medicine was involved.

  4. Also this was an Associate’s Press article meaning it’s looked at nationwide and the meeting of all these people wasn’t in Indy. Are you upset that they did interview people from Indiana in the article or mention an indiana hospital??

  5. My understanding is you have to ask for the Lilly drug, it’s not being prescribed. Also, have heard it works really well if you have it. I don’t know for a fact you have to request it but if so, I don’t get that. If anyone knows please respond.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In